Substance Abuse disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SBS003 MIFTS: 59	Substance Abuse Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse ¹² ²⁹ ³ ¹⁵

Substance-Related Disorders ⁴⁴ ⁷³

Substance Abuse Problem ⁷³

Classifications:

MalaCards categories:
Anatomical: Mental diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:302

MeSH ⁴⁴ D019966

NCIt ⁵⁰ C16522

SNOMED-CT ⁶⁸ 26416006

UMLS ⁷³ C0013146 C0740858 C0236969

Sources

Summaries for Substance Abuse

Disease Ontology : ¹² A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to eating disorder and cocaine abuse, and has symptoms including symptoms An important gene associated with Substance Abuse is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Amphetamine and Buprenorphine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

CDC : ³ Data are for the U.S.

Wikipedia : ⁷⁶ Substance abuse, also known as drug abuse, is a patterned use of a drug in which the user consumes the... more...

Sources

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 156)

#	Related Disease	Score	Top Affiliating Genes
1	eating disorder	32.4	BDNF COMT DRD2 NPY SLC6A3 SLC6A4
2	cocaine abuse	32.2	DBH DRD2 PRL SLC6A3 SLC6A4
3	impulse control disorder	31.9	DRD2 DRD3 DRD4
4	alcohol abuse	31.7	ABCB7 BDNF DRD2 DRD3 DRD4 GABRA2
5	depression	31.3	BDNF MAOA SLC6A4
6	antisocial personality disorder	30.7	COMT DRD2 HTR1B MAOA SLC6A3 SLC6A4
7	anxiety	30.6	BDNF COMT CYP2D6 MAOA NPY SLC6A4
8	personality disorder	30.4	BDNF COMT DRD2 DRD4 HTR1B MAOA
9	movement disease	30.4	DRD2 DRD3 SLC6A3
10	pathological gambling	30.4	DRD2 DRD3 DRD4 MAOA SLC6A3 SLC6A4
11	post-traumatic stress disorder	30.3	BDNF COMT DRD2 MAOA SLC6A4
12	borderline personality disorder	30.2	BDNF COMT HTR1B MAOA SLC6A4
13	conduct disorder	30.2	COMT DBH DRD2 DRD4 DRD5 MAOA
14	traumatic brain injury	30.2	BDNF COMT DRD2
15	brain injury	30.2	BDNF COMT DRD2
16	opiate dependence	30.2	DRD2 DRD3 SLC6A4
17	psychotic disorder	30.1	BDNF COMT CYP2D6 DRD2 DRD3 DRD4
18	gilles de la tourette syndrome	30.0	BDNF COMT DBH DRD2 DRD4 DRD5
19	generalized anxiety disorder	30.0	BDNF COMT DRD2 MAOA SLC6A4
20	mood disorder	30.0	BDNF COMT DRD2 DRD3 DRD4 HTR1B
21	tobacco addiction	30.0	COMT DRD2 MAOA SLC6A3 SLC6A4
22	bipolar disorder	30.0	BDNF COMT DBH DRD2 DRD3 DRD4
23	alexithymia	30.0	COMT DRD2 SLC6A4
24	disease of mental health	30.0	BDNF COMT CYP2D6 DRD2 DRD3 DRD4
25	avoidant personality disorder	30.0	MAOA SLC6A4
26	bipolar i disorder	29.9	BDNF COMT SLC6A4
27	tardive dyskinesia	29.9	COMT CYP2D6 DRD2 DRD3
28	anorexia nervosa	29.7	BDNF COMT NPY PRL SLC6A4
29	schizoaffective disorder	29.7	BDNF COMT DRD2 DRD3 PRL SLC6A4
30	substance dependence	29.5	BDNF CYP2D6 DRD2 DRD3 DRD4 DRD5
31	schizophrenia	29.3	BDNF COMT CYP2D6 DBH DRD2 DRD3
32	attention deficit-hyperactivity disorder	29.2	BDNF COMT CYP2D6 DBH DRD2 DRD3
33	alcohol dependence	29.2	BDNF COMT DBH DRD2 DRD3 DRD4
34	autism	29.1	BDNF COMT DBH DRD2 DRD3 DRD4
35	cannabis abuse	11.4
36	panic disorder 1	11.1
37	opioid abuse	11.1
38	antidepressant type abuse	11.1
39	hallucinogen abuse	11.1
40	phencyclidine abuse	11.1
41	amphetamine abuse	11.1
42	barbiturate abuse	11.1
43	learning disability	11.1
44	withdrawal disorder	11.0
45	hepatitis	10.3
46	early-onset schizophrenia	10.2	BDNF DRD2
47	hepatitis c	10.2
48	polysubstance abuse	10.2	COMT DRD2 DRD3
49	alcohol-induced mental disorder	10.2	DRD2 SLC6A3 SLC6A4
50	alcoholic psychosis	10.2	DRD2 SLC6A3 SLC6A4

Graphical network of the top 20 diseases related to Substance Abuse:

Sources

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:

symptoms

MGI Mouse Phenotypes related to Substance Abuse:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.34	BDNF COMT CYBB DBH DRD2 DRD3
2	homeostasis/metabolism	MP:0005376	10.16	ABCB7 BDNF COMT CYBB DBH DRD2
3	cardiovascular system	MP:0005385	10.1	ABCB7 COMT CYBB DBH DRD2 DRD3
4	growth/size/body region	MP:0005378	10.06	ABCB7 BDNF CYBB DBH DRD2 DRD3
5	endocrine/exocrine gland	MP:0005379	10.02	BDNF COMT DBH DRD2 DRD5 HTR1B
6	adipose tissue	MP:0005375	9.93	CYBB DBH DRD2 DRD3 HTR1B NPY
7	integument	MP:0010771	9.76	BDNF DBH DRD2 GABRA2 PRL SLC6A3
8	mortality/aging	MP:0010768	9.73	ABCB7 BDNF CYBB DBH DRD2 DRD3
9	nervous system	MP:0003631	9.53	ABCB7 BDNF COMT CYBB DBH DRD2

Sources

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 340)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Amphetamine

Approved, Illicit, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

300-62-9

5826 3007

Buprenorphine

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

52485-79-7

40400 644073

Varenicline

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

249296-44-4

5310966

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

93-14-1

3516

Methadone

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

76-99-3

4095

Dopamine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

51-61-6, 62-31-7

681

Ziprasidone

Approved

Phase 4

146939-27-7

60854

Aripiprazole

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

129722-12-9

60795

Cocaine

Approved, Illicit

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

50-36-2

5760 446220

Naloxone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

465-65-6

5284596

Ethanol

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

64-17-5

702

Naltrexone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

16590-41-3

5360515

Bupropion

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

34841-39-9, 34911-55-2

444

Disulfiram

Approved

Phase 4,Phase 1

97-77-8

3117

Methylphenidate

Approved, Investigational

Phase 4,Phase 3,Phase 2

113-45-1

4158

Methamphetamine

Approved, Illicit

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

537-46-2

10836

Valproic Acid

Approved, Investigational

Phase 4,Phase 3,Not Applicable

99-66-1

3121

Risperidone

Approved, Investigational

Phase 4,Phase 3

106266-06-2

5073

Nicotine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

54-11-5

942 89594

Ribavirin

Approved

Phase 4,Phase 3,Not Applicable

36791-04-5

37542

Paroxetine

Approved, Investigational

Phase 4

61869-08-7

43815

Lorazepam

Approved

Phase 4

846-49-1

3958

Clozapine

Approved

Phase 4

5786-21-0

2818

Emtricitabine

Approved, Investigational

Phase 4

143491-57-0

60877

Dextroamphetamine

Approved, Illicit

Phase 4,Phase 2,Phase 1

51-64-9

5826

Citalopram

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

59729-33-8

2771

Sofosbuvir

Approved

Phase 4,Phase 3

1190307-88-0

45375808

Allopurinol

Approved

Phase 4

315-30-0

2094

Choline

Approved, Nutraceutical

Phase 4,Not Applicable

62-49-7

305

Creatine

Approved, Investigational, Nutraceutical

Phase 4

57-00-1

586

Heroin

Illicit, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

561-27-3

5462328

Betadex

Experimental

Phase 4

7585-39-9

320761

Tenofovir

Experimental, Investigational

Phase 4

147127-20-6

464205

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Narcotic Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Central Nervous System Depressants

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Analgesics, Opioid

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Narcotics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Cholinergic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Respiratory System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antitussive Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Nicotinic Agonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Chlorpheniramine, phenylpropanolamine drug combination

Phase 4,Phase 3,Phase 2,Not Applicable

Adrenergic Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Neurotransmitter Uptake Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Atomoxetine Hydrochloride

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Serotonin Agents

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

Serotonin Antagonists

Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1051)

#	Name	Status	NCT ID	Phase	Drugs
1	Cognitive Correlates of Substance Abuse - 11	Unknown status	NCT00000346	Phase 4
2	Integrating Buprenorphine Into HIV Treatment	Unknown status	NCT00241930	Phase 4
3	Smoking Cessation Treatment for Methadone Maintenance Patients	Unknown status	NCT01027754	Phase 4	Varenicline;Placebo
4	Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)	Unknown status	NCT01339286	Phase 4	atomoxetine
5	The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation	Unknown status	NCT02935998	Phase 4	Ziprasidone
6	Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units	Unknown status	NCT01825057	Phase 4
7	Buprenorphine and Integrated HIV Care Evaluation	Unknown status	NCT00124358	Phase 4	Buprenorphine
8	Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse	Completed	NCT00223197	Phase 4	Pregnenolone
9	Depakote ER Therapy for Mania Comorbid With Substance Abuse	Completed	NCT00208195	Phase 4	Divalproex ER
10	Abilify Therapy for Reducing Comorbid Substance Abuse	Completed	NCT00208169	Phase 4	Aripiprazole
11	Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)	Completed	NCT00798538	Phase 4
12	Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse	Completed	NCT00573534	Phase 4	Vyvanse
13	Facilitating the Adoption of Evidence-Based Depression Management in Substance Use Treatment Programs	Completed	NCT00137306	Phase 4
14	Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder	Completed	NCT00203528	Phase 4	divalproex sodium ER;risperidone
15	Smoking Cessation in Alcoholism Treatment	Completed	NCT00000454	Phase 4	nicotine replacement patch
16	Citicoline for Bipolar 1 Disorder and Cocaine Dependence	Completed	NCT00619723	Phase 4	Citicoline;Placebo
17	The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients	Completed	NCT00295412	Phase 4	quetiapine (drug)
18	Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")	Completed	NCT00955162	Phase 4	Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)
19	The Whole Day First Grade Program	Completed	NCT00257088	Phase 4
20	Study of Aripiprazole in Subjects With Alcoholism	Completed	NCT00082199	Phase 4	Aripiprazole;Placebo
21	Improving Hepatitis C Treatment in Injection Drug Users	Completed	NCT00148031	Phase 4	Pegylated Interferon and Ribavirin
22	Use of Naltrexone in a Clinical Setting	Completed	NCT00000445	Phase 4	naltrexone (Revia)
23	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder	Completed	NCT00156715	Phase 4	Quetiapine
24	Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence	Completed	NCT00330239	Phase 4	Paroxetine CR
25	Relapse Prevention With Varenicline	Completed	NCT00944554	Phase 4	Varenicline;Placebo
26	Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation	Completed	NCT00484692	Phase 4	sustained-release bupropion (Zyban(R))
27	Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia	Completed	NCT00208143	Phase 4	Quetiapine;Risperidone
28	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder	Completed	NCT00130923	Phase 4	Risperidone Long Acting;oral risperidone
29	Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT)	Completed	NCT00326781	Phase 4	Nicoderm Transdermal Patch;Nicotine Nasal Spray
30	Naltrexone Treatment for Alcoholic Women	Completed	NCT00000448	Phase 4	naltrexone;Placebo
31	Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder	Completed	NCT00721526	Phase 4	disulfiram plus lorazepam
32	Naltrexone for Heavy Drinking in Young Adults	Completed	NCT00568958	Phase 4	naltrexone;placebo naltrexone
33	Treatment of Patients With Alcoholism and Attention Deficit Disorder	Completed	NCT00261872	Phase 4	Methylphenidate
34	Creatine as a Treatment Option for Depression in Methamphetamine Using Females	Completed	NCT01514630	Phase 4	Creatine monohydrate
35	Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia	Completed	NCT02396979	Phase 4	Methadone
36	Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism	Completed	NCT00920829	Phase 4	Naltrexone 50 Mg;Placebo
37	Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual	Completed	NCT00498550	Phase 4	Clozapine;Treatment as usual
38	Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist	Completed	NCT01673594	Phase 4	SODAS MPH;Naltrexone
39	Buprenorphine and Integrated HIV Care	Completed	NCT00317460	Phase 4
40	Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment	Completed	NCT00844272	Phase 4
41	PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5	Completed	NCT02149888	Phase 4	Tenofovir/emtricitabine
42	Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection	Recruiting	NCT03057847	Phase 4	Sofosbuvir/Velpatasvir
43	Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder	Recruiting	NCT02566824	Phase 4	Methylphenidate or amphetamine product
44	Houston Emergency Opioid Engagement System	Recruiting	NCT03396276	Phase 4	Suboxone
45	Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO)	Active, not recruiting	NCT01936857	Phase 4	Buprenorphine/naloxone;Methadone Maintenance Therapy
46	Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care	Enrolling by invitation	NCT03093415	Phase 4	elbasvir-grazoprevir (50 mg/100 mg)
47	Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use	Not yet recruiting	NCT03266445	Phase 4	buprenorphine/naloxone
48	Telemonitoring of Uncontrolled Hypertension	Not yet recruiting	NCT02730052	Phase 4
49	Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk	Not yet recruiting	NCT03781765	Phase 4	Methylphenidate;Atomoxetine
50	Buprenorphine as a Treatment in Opiate Dependent Pain Patients	Terminated	NCT00552578	Phase 4	buprenorphine/naloxone;buprenorphine/naloxone

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

desipramine

desipramine hydrochloride

doxapram

doxapram hydrochloride

Cochrane evidence based reviews: substance-related disorders

Sources

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

#	Genetic test	Affiliating Genes
1	Substance Abuse ²⁹

Sources

Anatomical Context for Substance Abuse

MalaCards organs/tissues related to Substance Abuse:

⁴¹

Testes, Brain, Cortex, Heart, Kidney, Liver, Lung

Sources

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 1451)

#	Title	Authors	Year
1	Communitarianism and youth empowerment: Motivation for participation in a community-based substance abuse prevention coalition. ( 30506929 )	Bermea AM...Reid RJ	2019
2	Examining the Role of Substance Abuse in Elder Mistreatment: Results From Mistreatment Investigations. ( 27044491 )	Conrad KJ...Iris M	2019
3	Understanding child protection decisions involving parents with mental illness and substance abuse. ( 29772468 )	Roscoe J.N....Chambers J.E.	2018
4	Primary Hip and Knee Arthroplasty in a Safety Net Hospital: Substance Abuse and Other Factors Affecting Short-term Complications. ( 29853309 )	Jergesen H.E....Yi P.H.	2018
5	Relationships between substance abuse/dependence and psychiatric disorders based on polygenic scores. ( 29974660 )	GurriarA!n X....Costas J.	2018
6	Why Don't Hospitals Prioritize Substance Abuse in Their Community Benefit Programming? ( 29346190 )	Franz B....Kelleher K.	2018
7	Interventions for Women With Substance Abuse Issues: A Scoping Review. ( 29426381 )	Leppard A....Davis J.A.	2018
8	Child maltreatment severity, chronic substance abuse, and disability status. ( 29878835 )	O'Sullivan D....Shenk C.	2018
9	Psychoactive substance abuse and dependence and its association with anxiety disorders: a population-based study of young adults in Brazil. ( 29451585 )	de Matos M.B....Quevedo L.A.	2018
10	Barriers and Facilitators to Treatment Engagement Among Clients in Inpatient Substance Abuse Treatment. ( 29683040 )	Yang Y....Stearns A.E.	2018
11	Velopharyngeal dysfunction from intranasal substance abuse: Case series and review of literature. ( 29756302 )	You P....Husein M.	2018
12	Stigma as a Barrier to Substance Abuse Treatment Among Those With Unmet Need: An Analysis of Parenthood and Marital Status. ( 29307947 )	Stringer K.L....Baker E.H.	2018
13	Successful Use of Ketamine for Burst Suppression in Super Refractory Status Epilepticus Following Substance Abuse. ( 29422735 )	Mutkule D.P....Rajasri K.	2018
14	Detecting Recovery Problems Just in Time: Application of Automated Linguistic Analysis and Supervised Machine Learning to an Online Substance Abuse Forum. ( 29895517 )	Kornfield R....Gustafson D.H.	2018
15	Reward-Based Learning as a Function of Severity of Substance Abuse Risk in Drug-NaA^ve Youth with ADHD. ( 29924634 )	Parvaz M.A....Ivanov I.	2018
16	Victimization of the Substance Abuse and Sexual Behaviors among Junior High School Students in Cambodia. ( 29845023 )	Yen Y....Sohail M.T.	2018
17	Substance Abuse Surveillance among Construction Workers: A Proof of Concept Alternative Approach. ( 29303868 )	Caban-Martinez A.J....Reidy L.J.	2018
18	Adding Resistance Training to the Standard of Care for Inpatient Substance Abuse Treatment in Men With Human Immunodeficiency Virus Improves Skeletal Muscle Health Without Altering Cytokine Concentrations. ( 29257793 )	Vingren J.L....Hill D.W.	2018
19	Ambient air pollution exposure and emergency department visits for substance abuse. ( 29958279 )	Szyszkowicz M....Rowe B.H.	2018
20	Gender and Cultural Adaptations for Diversity: A Systematic Review of Alcohol and Substance Abuse Interventions for Latino Males. ( 29364763 )	Valdez L.A....Garcia D.O.	2018
21	Redeveloping Substance Abuse Treatment for Military Personnel. ( 29779198 )	Schrader C....Rahimi A.	2018
22	Characteristics of Substance Abuse and Self-Injury among American Indian Adolescents Who Have Engaged in Binge Drinking. ( 29889946 )	Cwik M.F....Barlow A.	2018
23	Perceptions of child protective services among pregnant or recently pregnant, opioid-using women in substance abuse treatment. ( 29433069 )		2018
24	Tobacco Cessation Interventions and Smoke-Free Policies in Mental Health and Substance Abuse Treatment Facilities - United States, 2016. ( 29746451 )		2018
25	Civil commitment laws for substance abuse treatment: An acceptable option? ( 29857597 )		2018
26	Web-Based Intervention to Reduce Substance Abuse and Depression: A Three Arm Randomized Trial in Mexico. ( 29768070 )		2018
27	Long-Term Implications Of A Short-Term Policy: Redacting Substance Abuse Data. ( 29863917 )		2018
28	The Untreated Addiction: Going Tobacco-Free in a VA Substance Abuse Residential Rehabilitation Treatment Program (SARRTP). ( 29721729 )		2018
29	Patterns of Substance Abuse in Offenders With Schizophrenia- Illness-Related or Criminal Life-Style? ( 29946271 )		2018
30	Cervical dystonia and substance abuse. ( 29569175 )		2018
31	Pulmonary Alveolar Proteinosis in Setting of Inhaled Toxin Exposure and Chronic Substance Abuse. ( 29607238 )		2018
32	Cultural and Social Predictors of Substance Abuse Recovery among American Indian and Non-American Indian Pregnant and Parenting Women. ( 29932824 )		2018
33	Intravenous Valproic Acid Add-On Therapy in Acute Agitation Adolescents With Suspected Substance Abuse: A Report of Six Cases. ( 29303801 )		2018
34	A Shared Decision-Making Tool to Prevent Substance Abuse: Protocol for a Randomized Controlled Trial. ( 29326094 )		2018
35	Burden of Schizophrenia or Psychosis-Related Symptoms in Adults Undergoing Substance Abuse Evaluation. ( 29905667 )		2018
36	The case for considering rather than ignoring race/ethnicity in substance abuse research. ( 29388881 )		2018
37	Cued for risk: Evidence for an incentive sensitization framework to explain the interplay between stress and anxiety, substance abuse, and reward uncertainty in disordered gambling behavior. ( 30357661 )	Hellberg SN...Robinson MJF	2018
38	The development of anxiety symptomatology among juvenile offenders: the roles of maternal substance abuse and unemployment. ( 30236038 )	Wojciechowski TW	2018
39	Comorbid Depression and Substance Abuse in Domestic Homicide: Missed Opportunities in the Assessment and Management of Mental Illness in Perpetrators. ( 30486719 )	Oliver CL...Jaffe PG	2018
40	Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disorders. ( 29360053 )	M?rkved N...L?berg EM	2018
41	Veterans in substance abuse treatment program self-initiate box gardening as a stress reducing therapeutic modality. ( 29458930 )	Lehmann LP...Detweiler MB	2018
42	Employment services and substance abuse treatment. ( 29471929 )	Sherba RT...Linley JV	2018
43	Substance abuse treatment engagement, completion and short-term outcomes in the Western Cape province, South Africa: Findings from the Service Quality Measures Initiative. ( 29482052 )	Myers B...Koch JR	2018
44	Psychosocial Factors that Shape Substance Abuse and Related Mental Health of Women Military Veterans who Use Community-Based Services. ( 29485302 )	Evans EA...Hamilton AB	2018
45	Co-occurring Mental Disorders in Substance Abuse Treatment: the Current Health Care Situation in Germany. ( 29491767 )	Dauber H...Pogarell O	2018
46	Abstracts presented at the Association for Medical Education and Research in Substance Abuse (AMERSA) 41st Annual Conference, Washington, DC, USA, November 2017. ( 29509099 )	Gordon AJ	2018
47	Machine Learning of Functional Magnetic Resonance Imaging Network Connectivity Predicts Substance Abuse Treatment Completion. ( 29529409 )	Steele VR...Kiehl KA	2018
48	Recommendations for Substance Abuse and Pain Control in Patients with Chronic Pain. ( 29556830 )	Vadivelu N...Urman RD	2018
49	Evaluation of the Substance Abuse Research and Education Training (SARET) program: Stimulating health professional students to pursue careers in substance use research. ( 29565782 )	Hanley K...Gourevitch MN	2018
50	Can We Predict Which Adolescents Will Engage in Outpatient Substance Abuse Treatment? ( 29568221 )	Christie GI...Wills S	2018

Sources

Genes for Substance Abuse

Genes related to Substance Abuse (0 elite genes):

(show all 24)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MIAT	Myocardial Infarction Associated Transcript	RNA Gene	150	Experimental evidence: Expression ³⁹	20951849
2	DRD2	Dopamine Receptor D2	Protein Coding	24.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	TF	Transferrin	Protein Coding	24.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	SLC6A3	Solute Carrier Family 6 Member 3	Protein Coding	24.23	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	DRD4	Dopamine Receptor D4	Protein Coding	23.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	23.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	BDNF	Brain Derived Neurotrophic Factor	Protein Coding	23.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	DRD3	Dopamine Receptor D3	Protein Coding	22.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	COMT	Catechol-O-Methyltransferase	Protein Coding	22.56	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	HTR1B	5-Hydroxytryptamine Receptor 1B	Protein Coding	21.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	MAOA	Monoamine Oxidase A	Protein Coding	21.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	PRL	Prolactin	Protein Coding	21.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	NPY	Neuropeptide Y	Protein Coding	21.4	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6	Protein Coding	21.05	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	DBH	Dopamine Beta-Hydroxylase	Protein Coding	20.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	DRD5	Dopamine Receptor D5	Protein Coding	20.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	ABCB7	ATP Binding Cassette Subfamily B Member 7	Protein Coding	20.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	CYBB	Cytochrome B-245 Beta Chain	Protein Coding	19.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	TDO2	Tryptophan 2,3-Dioxygenase	Protein Coding	19.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	GABRA2	Gamma-Aminobutyric Acid Type A Receptor Alpha2 Subunit	Protein Coding	13.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	MOBP	Myelin-Associated Oligodendrocyte Basic Protein	Protein Coding	12.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	PLP1	Proteolipid Protein 1	Protein Coding	9.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	WASF2	WAS Protein Family Member 2	Protein Coding	7.84	DISEASES inferred ¹⁵
24	GGT2	Gamma-Glutamyltransferase 2	Protein Coding	7	DISEASES inferred ¹⁵

Sources

Variations for Substance Abuse

Sources

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Sources

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 21)

#	Super pathways	Score	Top Affiliating Genes
1	Peptide ligand-binding receptors ⁶⁶ Show member pathways Class A/1 (Rhodopsin-like receptors) ⁶⁶ Defective AVP causes neurohypophyseal diabetes insipidus (NDI) ⁶⁶ Formyl peptide receptors bind formyl peptides and many other ligands ⁶⁶ G alpha (i) signalling events ⁶⁶ GPCR ligand binding ⁶⁶ GPCRs, Class A Rhodopsin-like ¹ Neuroactive ligand-receptor interaction ³⁷ Orexin and neuropeptides FF and QRFP bind to their respective receptors ⁶⁶ Peptide GPCRs ¹ Tachykinin receptors bind tachykinins ⁶⁶ Vasopressin-like receptors ⁶⁶	13.44	DRD2 DRD3 DRD4 DRD5 GABRA2 HTR1B
2	Circadian entrainment ³⁷ Show member pathways Cholinergic synapse ³⁷ Dopaminergic synapse ³⁷ Estrogen signaling pathway ³⁷ Glutamatergic synapse ³⁷ Relaxin receptors ⁶⁶ Relaxin signaling pathway ³⁷ Synaptic Neurotransmission Pathways: Glutamatergic Excitation ⁶⁵	12.82	COMT DRD2 DRD3 DRD4 DRD5 MAOA
3	Beta-Adrenergic Signaling ⁶⁴ Show member pathways CDK5 Pathway ⁶⁴ Erythropoietin Pathway ⁶⁴ Insulin Receptor Pathway ⁶⁴	12.65	BDNF DRD2 DRD3 DRD4 DRD5
4	Dopamine-DARPP32 Feedback onto cAMP Pathway ⁶⁴	12.19	DRD2 DRD3 DRD4 DRD5
5	Circadian rythm related genes ¹	12.13	DRD2 DRD3 DRD4 SLC6A4
6	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	12.01	BDNF MAOA SLC6A4 TF
7	cAMP signaling pathway ³⁷ Show member pathways Hydroxycarboxylic acid-binding receptors ⁶⁶	11.96	BDNF DRD2 DRD5 HTR1B NPY
8	Amphetamine addiction ³⁷ Show member pathways Cocaine addiction ³⁷	11.85	BDNF DRD2 MAOA SLC6A3
9	Serotonergic synapse ³⁷	11.82	CYP2D6 HTR1B MAOA SLC6A4
10	Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics ⁶¹ Show member pathways Nicotine Activity on Dopaminergic Neurons ¹ SNARE interactions in vesicular transport ³⁷	11.78	DRD2 DRD3 DRD4
11	Amino Acid metabolism ¹	11.71	DBH MAOA TDO2
12	Phenylalanine metabolism ³⁷ Show member pathways 4-hydroxybenzoate biosynthesis ¹ Phenylalanine, tyrosine and tryptophan biosynthesis ³⁷ Tyrosine metabolism ³⁷ Tyrosine metabolism p.1 (dopamine) ²²	11.61	COMT DBH MAOA
13	Monoamine GPCRs ¹ Show member pathways Adrenaline signalling through Alpha-2 adrenergic receptor ⁶⁶ Adrenoceptors ⁶⁶ Amine ligand-binding receptors ⁶⁶ Dopamine receptors ⁶⁶ Histamine receptors ⁶⁶ Muscarinic acetylcholine receptors ⁶⁶ Serotonin receptors ⁶⁶	11.61	DRD2 DRD3 DRD4 DRD5 HTR1B
14	Clomipramine Pathway, Pharmacokinetics ⁶¹ Show member pathways Amitriptyline and Nortriptyline Pathway, Pharmacokinetics ⁶¹ Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2 ⁶⁶ Citalopram Pathway, Pharmacokinetics ⁶¹ Clopidogrel Pathway, Pharmacokinetics ⁶¹ Colchicine Metabolic Pathway ¹ Imipramine/Desipramine Pathway, Pharmacokinetics ⁶¹ Lidocaine metabolism ¹ Olanzapine Pathway, Pharmacokinetics ⁶¹ Paroxetine Pathway, Pharmacokinetics ⁶¹ Proton Pump Inhibitor Pathway, Pharmacokinetics ⁶¹ Venlafaxine Pathway, Pharmacokinetics ⁶¹ Verapamil Pathway, Pharmacokinetics ⁶¹	11.56	COMT CYP2D6 SLC6A4
15	Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics ⁶¹	11.06	HTR1B MAOA SLC6A4
16	Biogenic Amine Synthesis ¹ Show member pathways catecholamine biosynthesis ¹ Catecholamine biosynthesis ⁶⁶	10.89	COMT DBH MAOA
17	DARPP-32 Phosphorylation ⁶⁵	10.84	DRD2 DRD3 DRD5
18	noradrenaline and adrenaline degradation ¹ Show member pathways Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB ⁶⁶ dopamine degradation ¹ melatonin degradation II ¹	10.77	COMT MAOA
19	Dopamine metabolism ¹	10.73	COMT MAOA
20	Neurotransmitter Clearance In The Synaptic Cleft ⁶⁶ Show member pathways Dopamine clearance from the synaptic cleft ⁶⁶ Enzymatic degradation of dopamine by COMT ⁶⁶ Enzymatic degradation of Dopamine by monoamine oxidase ⁶⁶ L-dopa degradation ¹ Metabolism of serotonin ⁶⁶ Serotonin clearance from the synaptic cleft ⁶⁶	10.67	COMT MAOA SLC6A3 SLC6A4
21	Monoamine Transport ¹ Show member pathways Serotonin Transporter Activity ¹	10.65	DBH MAOA SLC6A3 SLC6A4 TDO2

Sources

GO Terms for Substance Abuse

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	integral component of plasma membrane	GO:0005887	9.91	CYBB DRD2 DRD3 DRD4 DRD5 GABRA2
2	axon	GO:0030424	9.83	BDNF COMT DRD2 GABRA2 SLC6A3
3	endocytic vesicle	GO:0030139	9.63	DRD2 DRD3 TF
4	integral component of postsynaptic membrane	GO:0099055	9.58	DRD2 SLC6A3 SLC6A4
5	integral component of presynaptic membrane	GO:0099056	9.46	DRD2 HTR1B SLC6A3 SLC6A4
6	serotonergic synapse	GO:0099154	9.32	HTR1B SLC6A4
7	dendrite	GO:0030425	9.17	BDNF COMT CYBB DRD2 DRD4 GABRA2
8	dopaminergic synapse	GO:0098691	9.13	DRD2 DRD3 SLC6A3
9	integral component of membrane	GO:0016021	10.21	ABCB7 COMT CYBB CYP2D6 DBH DRD2

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

(show top 50) (show all 51)

#	Name	GO ID	Score	Top Affiliating Genes
1	chemical synaptic transmission	GO:0007268	9.91	DBH DRD4 DRD5 GABRA2 HTR1B NPY
2	cellular calcium ion homeostasis	GO:0006874	9.88	DRD3 DRD4 DRD5
3	response to nutrient	GO:0007584	9.87	CYBB PRL SLC6A4
4	locomotory behavior	GO:0007626	9.87	DBH DRD2 DRD3 SLC6A3
5	memory	GO:0007613	9.86	BDNF DBH SLC6A4
6	G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	GO:0007187	9.83	DRD4 HTR1B NPY
7	social behavior	GO:0035176	9.82	DRD3 DRD4 SLC6A4
8	visual learning	GO:0008542	9.82	DBH DRD2 DRD3
9	neurotransmitter transport	GO:0006836	9.81	GABRA2 SLC6A3 SLC6A4
10	response to ethanol	GO:0045471	9.8	DRD2 DRD3 HTR1B PRL SLC6A3
11	feeding behavior	GO:0007631	9.77	DRD2 HTR1B NPY
12	associative learning	GO:0008306	9.77	DBH DRD2 DRD5
13	negative regulation of blood pressure	GO:0045776	9.76	DRD2 DRD3 DRD5
14	arachidonic acid secretion	GO:0050482	9.75	DRD2 DRD3 DRD4
15	behavioral response to cocaine	GO:0048148	9.73	DRD2 DRD3 DRD4
16	dopamine receptor signaling pathway	GO:0007212	9.72	DRD2 DRD3 DRD4
17	adenylate cyclase-activating adrenergic receptor signaling pathway	GO:0071880	9.71	DRD2 DRD3
18	response to pain	GO:0048265	9.71	COMT DBH
19	response to iron ion	GO:0010039	9.71	DRD2 SLC6A3
20	negative regulation of protein secretion	GO:0050709	9.71	DRD2 DRD3 DRD4
21	vasoconstriction	GO:0042310	9.7	HTR1B SLC6A4
22	neurotransmitter biosynthetic process	GO:0042136	9.7	SLC6A3 SLC6A4
23	positive regulation of renal sodium excretion	GO:0035815	9.7	DRD2 DRD3
24	synaptic transmission, dopaminergic	GO:0001963	9.7	DRD2 DRD3 DRD5
25	regulation of postsynaptic neurotransmitter receptor internalization	GO:0099149	9.69	DRD3 DRD4
26	prepulse inhibition	GO:0060134	9.69	DRD2 DRD3 SLC6A3
27	adenylate cyclase-activating dopamine receptor signaling pathway	GO:0007191	9.68	DRD3 DRD5
28	catecholamine metabolic process	GO:0006584	9.68	COMT MAOA
29	neurotransmitter catabolic process	GO:0042135	9.68	COMT MAOA
30	regulation of dopamine metabolic process	GO:0042053	9.68	DRD4 SLC6A3
31	adenohypophysis development	GO:0021984	9.67	DRD2 SLC6A3
32	monoamine transport	GO:0015844	9.67	SLC6A3 SLC6A4
33	negative regulation of synaptic transmission, glutamatergic	GO:0051967	9.67	DRD2 HTR1B
34	G protein-coupled receptor internalization	GO:0002031	9.67	DRD2 DRD3 HTR1B
35	negative regulation of voltage-gated calcium channel activity	GO:1901386	9.66	DRD2 DRD4
36	drinking behavior	GO:0042756	9.66	DRD2 HTR1B
37	phospholipase C-activating dopamine receptor signaling pathway	GO:0060158	9.65	DRD2 DRD5
38	adenylate cyclase-inhibiting dopamine receptor signaling pathway	GO:0007195	9.65	DRD2 DRD3 DRD4
39	response to cocaine	GO:0042220	9.65	DRD2 DRD3 DRD5 HTR1B SLC6A3
40	regulation of dopamine uptake involved in synaptic transmission	GO:0051584	9.64	DRD2 DRD3
41	negative regulation of dopamine receptor signaling pathway	GO:0060160	9.63	DRD2 DRD3
42	behavioral response to ethanol	GO:0048149	9.63	DBH DRD2 DRD4
43	acid secretion	GO:0046717	9.62	DRD2 DRD3
44	fear response	GO:0042596	9.62	DBH DRD4
45	dopamine metabolic process	GO:0042417	9.62	COMT DRD2 DRD3 DRD4
46	positive regulation of dopamine uptake involved in synaptic transmission	GO:0051586	9.61	DRD2 DRD4
47	regulation of locomotion involved in locomotory behavior	GO:0090325	9.61	DRD2 DRD3
48	response to drug	GO:0042493	9.56	COMT CYBB DRD2 DRD3 HTR1B PRL
49	response to amphetamine	GO:0001975	9.55	DBH DRD2 DRD3 DRD4 DRD5
50	response to histamine	GO:0034776	9.54	DRD2 DRD3 DRD4

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	oxidoreductase activity	GO:0016491	9.85	CYBB CYP2D6 DBH MAOA TDO2
2	G protein-coupled receptor activity	GO:0004930	9.85	DRD2 DRD3 DRD4 DRD5 HTR1B NPY
3	drug binding	GO:0008144	9.63	CYP2D6 DRD2 DRD3 DRD4 HTR1B SLC6A3
4	adrenergic receptor activity	GO:0004935	9.48	DRD2 DRD3
5	neurotransmitter:sodium symporter activity	GO:0005328	9.43	SLC6A3 SLC6A4
6	dopamine neurotransmitter receptor activity, coupled via Gi/Go	GO:0001591	9.43	DRD2 DRD3 DRD4
7	serotonin binding	GO:0051378	9.4	HTR1B SLC6A4
8	monoamine transmembrane transporter activity	GO:0008504	9.32	SLC6A3 SLC6A4
9	dopamine neurotransmitter receptor activity	GO:0004952	9.26	DRD2 DRD3 DRD4 DRD5
10	dopamine binding	GO:0035240	9.02	DRD2 DRD3 DRD4 DRD5 SLC6A3

Sources

Sources for Substance Abuse

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Substance Abuse

Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Classifications:

External Ids:

Summaries for Substance Abuse

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Substance Abuse:

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:

MGI Mouse Phenotypes related to Substance Abuse:

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cochrane evidence based reviews: substance-related disorders

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

Anatomical Context for Substance Abuse

MalaCards organs/tissues related to Substance Abuse:

Publications for Substance Abuse

Articles related to Substance Abuse:

Genes for Substance Abuse

Genes related to Substance Abuse (0 elite genes):

Variations for Substance Abuse

Expression for Substance Abuse

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

GO Terms for Substance Abuse

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

Sources for Substance Abuse

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :